Precision oncology is shifting toward comprehensive transcriptome profiling to reveal fusions, splice variants, and expression changes that DNA panels miss. Yet obtaining reliable data from degraded ...
Healthcare Asia Magazine on MSN
Lucence, DXD Hub, and NCCS launch $6m UNITED 2.0 cancer test
The team will adopt a dual WES-WTS approach for more detailed tumour profiling. Lucence, Diagnostics Development Hub hosted ...
The three-year UNITED 2.0 initiative will use advanced DNA testing and AI to give doctors a more complete picture of a patient’s cancer and help match treatments more precisely.
The human lymphatic system is notoriously difficult to map due to its size and variability among individuals. Spatial ...
Caris received FDA approval in November 2024 for MI Cancer Seek, a tissue-based assay that is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing ...
Sacituzumab Govitecan Plus Pembrolizumab Shows Promise for Bladder Sparing in Muscle-Invasive Cancer
Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading ...
Caris Life Sciences ® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...
The origin of many diseases begins at the cellular level and involves multiple molecular interactions. However, previous methods have struggled to accurately observe changes in individual cells.
Morning Overview on MSN
Single-cell breakthrough decodes transcriptome, epigenome & 3D genome at once
A team led by Professor Inkyung Jung from the Department of Biological Sciences at KAIST, working with Professor Yarui Diao’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results